Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab in Advanced Renal Cell Cancer
NCT00019539Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 1998
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bevacizumab in renal cell carcinoma (RCC) (3 arms), sponsored by National Cancer Institute. Primary endpoint: Time to Progression. Started Nov 1998; status: completed.
02
Drugs
bevacizumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00019539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00019539.